For instance, Tyro3 was shown to contribute to the resistance to ICI treatment through inhibition of ferroptosis that is required for T cell‐mediated cancer cell killing, providing a combination therapy of a Tyro3 inhibitor and ICIs to treat these types of resistant patients.15 This evidence concerns the gene TYRO3 and cancer.